🌍AMR — A Global Health Emergency
The WHO describes antimicrobial resistance (AMR) as one of the top 10 global public health threats. In 2019, AMR was directly responsible for 1.27 million deaths and contributed to 4.95 million deaths worldwide.
WHO Priority Pathogens (Critical Priority)
CRITICAL
- Carbapenem-resistant Acinetobacter baumannii
- Carbapenem-resistant Pseudomonas aeruginosa
- Carbapenem-resistant Enterobacteriaceae (CRE)
HIGH PRIORITY
- MRSA (Methicillin-resistant S. aureus)
- ESBL-producing Enterobacteriaceae
- VRE (Vancomycin-resistant Enterococci)
- Fluoroquinolone-resistant Helicobacter pylori
MEDIUM PRIORITY
- Penicillin-resistant Streptococcus pneumoniae
- Ampicillin-resistant Haemophilus influenzae
- Fluoroquinolone-resistant Salmonella
🎯AMS Programme Goals
- Optimal selection — right antibiotic for the right infection based on culture & sensitivity
- Optimal dose — correct dosing based on weight, renal function, site of infection
- Optimal duration — shortest effective course; avoid prolonged empirical therapy
- Optimal route — IV when necessary, switch to oral as soon as clinically appropriate
- Prevent C. difficile — minimise broad-spectrum antibiotic exposure
- Reduce costs — unnecessary IV antibiotics are expensive; oral bioequivalents cheaper
🇬🇧GCC AMR Burden
GCC hospitals report resistance rates significantly above global averages for several organisms, driven by OTC antibiotic availability, high antibiotic usage, and international patient movement.
🏪OTC Antibiotics in GCC
Major resistance driver: Historically, antibiotics were dispensed in GCC pharmacies without prescription. Patients self-treat viral infections, incomplete courses are common, and subtherapeutic doses select resistant organisms.
- Saudi Arabia, UAE, Qatar, Kuwait, Bahrain, Oman have all introduced stricter pharmacy regulations since 2014
- Prescription requirement enforcement has improved but inconsistently applied across sectors
- Cross-border purchase and "leftover" antibiotics from previous prescriptions remain common
- Patient education about antibiotic appropriateness is a core nursing responsibility
👩⚕️The Nurse's Role in AMS
- Administer on time — especially first dose in sepsis (<1 hour)
- Advocate for IV-to-oral switch — identify eligible patients daily and raise with prescriber
- Monitor culture results — flag when empirical therapy doesn't match sensitivities
- Check antibiotic duration — alert prescriber at 48–72 hrs if no review documented
- Educate patients — why antibiotics are being given, expected duration, side effects
- Document accurately — allergy details, actual administration times, reasons for dose omissions
- Participate in ward rounds — AMS "antibiotic round" input with pharmacist/ID team
🧬How Resistance Develops
Mutation
- Spontaneous genetic mutations during bacterial replication
- Antibiotic selects for resistant mutants by killing susceptible bacteria
- Example: Fluoroquinolone resistance via DNA gyrase mutation in E. coli
- Sub-therapeutic dosing accelerates selection pressure
Horizontal Gene Transfer (HGT)
- Conjugation — plasmids transfer resistance genes between bacteria (most common)
- Transformation — bacteria take up DNA from environment
- Transduction — bacteriophage carries resistance genes
- NDM (New Delhi Metallo-beta-lactamase) spreads via plasmid — can cross species
Beta-lactamase enzymes (ESBL, KPC, NDM, OXA-48) are the most clinically important resistance mechanisms in GCC hospitals. They inactivate penicillins, cephalosporins, and in some cases carbapenems.
🦠Key Resistant Organisms in GCC
MRSA — Methicillin-Resistant Staphylococcus aureus
Resistant to all beta-lactams. Treatment: Vancomycin (IV, monitor levels/AUC) or Daptomycin. Linezolid for SSTI.
Decolonisation
Contact Precautions
CHG Baths
Nasal Mupirocin
Nurse action: Decolonisation 5-day protocol before elective surgery. Screen high-risk admissions (recent hospital stay, dialysis, healthcare workers).
ESBL-Producing Enterobacteriaceae — Klebsiella pneumoniae, E. coli
Extended-Spectrum Beta-Lactamases hydrolyse most penicillins and cephalosporins. Carbapenems remain active (ertapenem, meropenem) but use is restricted to prevent CRE emergence.
Carbapenem restriction
Contact Precautions
Nitrofurantoin for UTI
Nurse action: Apply contact precautions. Report positive cultures urgently. Check empirical cephalosporins are de-escalated when ESBL confirmed.
CRE — Carbapenem-Resistant Enterobacteriaceae (KPC, NDM, OXA-48)
Near pan-resistant. Treatment: Ceftazidime-avibactam (KPC, OXA-48), Meropenem-vaborbactam, Colistin (last resort — nephrotoxic). Mortality up to 50% in bloodstream infection.
CRITICAL — Report immediately
Enhanced Contact Precautions
Cohorting required
Nurse action: Immediate contact precautions. Notify infection control. Cohort patient. Screen close contacts. Do NOT de-isolate without IC clearance.
VRE — Vancomycin-Resistant Enterococci
Resistant to vancomycin (and ampicillin in VanA). Treatment: Linezolid or Daptomycin. Colonisation is common; treatment only for true infection.
Contact Precautions
Linezolid monitor
Nurse action: Monitor Linezolid — CBC weekly (thrombocytopenia, anaemia). Avoid concurrent serotonergic drugs.
CRAB — Carbapenem-Resistant Acinetobacter baumannii
Most prevalent in GCC ICUs — 60–80% carbapenem resistance. Survives on dry surfaces for weeks. Treatment: Colistin ± Sulbactam ± Rifampicin. Cefiderocol is an emerging option.
Endemic in many GCC ICUs
Contact + Enhanced environmental cleaning
Nurse action: Rigorous environmental decontamination. Ventilator bundle compliance. Alert IC team for any new positive result. Colistin — monitor renal function daily.
Clostridioides difficile (C. diff)
Toxin-producing organism causing antibiotic-associated colitis. Spore-forming — alcohol gel DOES NOT kill spores. Only soap and water for hand hygiene with C. diff patients.
SOAP + WATER only
NO alcohol gel on hands
Contact Precautions
Treatment: Fidaxomicin (preferred) or Oral Vancomycin. NOT IV vancomycin. Do NOT give anti-motility agents before stool sample. Avoid PPIs if possible.
📊Antibiogram Interpretation for Nurses
Key Terms
MIC (Minimum Inhibitory Concentration)Lowest drug concentration that inhibits visible growth
Sensitive (S)Standard dosing likely to achieve clinical success
Intermediate (I)May work with higher dose or at site of accumulation (urine)
Resistant (R)Standard treatment likely to fail — do NOT use
Susceptible dose-dependent (SDD)Activity depends on achieving high drug exposure
When to Escalate Culture Results URGENTLY
- Blood culture positive with any organism — same day
- CRE / CRAB / NDM identified
- Empirical antibiotic shown RESISTANT on sensitivity
- No antibiotic sensitivity (pan-resistant)
- Organism identified but no antibiotic prescribed yet
- Patient clinically deteriorating and cultures pending >48h
⬇️De-escalation
De-escalation = switching from broad-spectrum empirical antibiotics to a narrower, targeted antibiotic once culture results are available.
- Most patients started on broad-spectrum cover should be reviewed at 48–72 hours
- If cultures show a sensitive organism — narrow the antibiotic
- If cultures negative at 48–72h and patient improving — consider stopping
- Nurse role: Flag to prescriber if cultures have returned and antibiotics have not been reviewed
- Document: "Culture results available — antibiotic review requested" in nursing notes
The failure to de-escalate is one of the biggest drivers of antibiotic resistance in hospitals. Nurses are key in prompting this review.
💊➡️💧IV to Oral Switch
Criteria for IV→Oral Switch
- Afebrile for >24 hours (temp <37.8°C)
- Clinically improving (HR, BP, WBC trending towards normal)
- Tolerating oral intake (no vomiting, functional GI tract)
- Causative organism sensitive to available oral antibiotic
- No concern about oral absorption (e.g., severe ileus, malabsorption)
Excellent Oral Bioavailability (>90%)
Amoxicillin
Ciprofloxacin
Metronidazole
Fluconazole
Linezolid
Doxycycline
Trimethoprim
Clarithromycin
For these drugs — IV and oral are clinically equivalent. IV continuation is unjustifiable once oral criteria met. Oral is safer (less CLABSI risk), cheaper, and allows earlier discharge.
🧪Culture Before Antibiotics
The principle: Collect all relevant cultures BEFORE the first antibiotic dose. Once antibiotics are given, culture yield drops significantly within 1–2 hours.
What to Collect
Sepsis / Bacteraemia2 sets blood cultures (different sites) — aerobic + anaerobic bottles
Suspected UTIMSU or catheter specimen — clean catch technique
Respiratory InfectionSputum or BAL (mechanically ventilated); pneumococcal/legionella urinary antigen
Wound InfectionDeep wound swab or tissue biopsy (avoid surface swabs)
MeningitisLP if no contraindication — do NOT delay antibiotics >30 min waiting for LP
In sepsis: cultures can be drawn simultaneously with antibiotic preparation. The 1-hour target for antibiotic administration takes priority over cultures.
⏱️Antibiotic Duration Evidence
- Community-acquired pneumonia (CAP) — 5 days if improving (IDSA/BTS)
- Uncomplicated UTI — 3–5 days for trimethoprim; 5–7 days nitrofurantoin
- Complicated UTI / Pyelonephritis — 7 days IV then oral
- Skin/soft tissue (cellulitis) — 5–7 days
- HAP/VAP — 7–8 days (shorter courses non-inferior to 14+ days)
- Bacteraemia (no source) — 14 days minimum from first negative culture
- Osteomyelitis — 4–6 weeks (oral if high bioavailability)
- Endocarditis — 4–6 weeks depending on organism and valve
"Complete the course" is outdated advice for many infections. Evidence shows shorter courses are non-inferior and safer. Nurses should clarify with prescriber the intended stop date.
🔪Surgical Antibiotic Prophylaxis
- Goal: Prevent surgical site infection (SSI) — NOT treat infection
- Single pre-operative dose — give within 60 min before incision
- Re-dose intraoperatively if surgery >3h or major blood loss
- Stop within 24 hours post-operatively for most procedures
- Continuing prophylaxis beyond 24h does NOT reduce SSI and increases resistance
Nurse vigilance: Prophylaxis antibiotics ordered post-operatively for multiple days are a very common AMS violation. If surgical prophylaxis continues beyond 24 hours without a documented therapeutic indication, query with the surgical team or AMS pharmacist.
🦰Urinary Tract Infection (UTI)
Community (Uncomplicated)
First-lineTrimethoprim 200mg BD x5d OR Nitrofurantoin 100mg MR BD x5d
AlternativePivmecillinam (where available) or Fosfomycin 3g single dose
GCC WARNING: Fluoroquinolone (ciprofloxacin) resistance in community E. coli is 35–55% in GCC. Do not use ciprofloxacin as first-line for uncomplicated UTI unless local antibiogram supports it.
Systemically Unwell / Pyelonephritis
IV therapyCeftriaxone 1g IV OD or Co-amoxiclav 1.2g IV TDS
ESBL riskErtapenem 1g IV OD (discuss with ID/pharmacy)
Switch oralWhen afebrile, tolerating oral — co-amoxiclav or based on cultures
Duration7 days total (IV + oral combined)
🫁Community-Acquired Pneumonia (CAP)
Mild-Moderate (CURB-65 score 0–2)
First-lineAmoxicillin 500mg–1g TDS PO
+ Atypical coverAdd Clarithromycin 500mg BD or Doxycycline 100mg BD
Duration5 days (if improving at 3 days)
Avoid fluoroquinolones (levofloxacin/moxifloxacin) for mild CAP — reserve for penicillin-allergic or treatment failure due to TB masquerade risk and resistance selection.
Severe (CURB-65 3–5 / ICU admission)
IV therapyCo-amoxiclav 1.2g TDS IV + Azithromycin 500mg OD IV/PO
Penicillin allergyLevofloxacin 500mg BD IV
Legionella/PneumococcalUrinary antigen — positive guides therapy intensity
Duration5–7 days; de-escalate at 72h review
🏥HAP / VAP (Hospital/Ventilator-Acquired Pneumonia)
Always follow your hospital's local antibiogram for HAP/VAP — local resistance patterns vary enormously. The guidance below is a framework only.
Low-risk HAP (no MDR risk)Piperacillin-tazobactam 4.5g TDS-QDS IV
High MDR risk / VAPMeropenem 1g TDS IV ± Vancomycin (if MRSA risk)
CRAB suspicionColistin + Sulbactam ± Rifampicin (ID consult)
Duration7–8 days (evidence for short courses non-inferior)
VAP Bundle (Nurse-Driven)
- Head-of-bed elevation 30–45°
- Oral care with chlorhexidine every 4–6 hours
- Cuff pressure monitoring (20–30 cmH₂O)
- Daily sedation interruption and weaning assessment
- Subglottic suctioning if available
🩹Skin & Soft Tissue Infections
Mild cellulitisFlucloxacillin 500mg QDS PO (Cefalexin if pen allergy)
Moderate (IV needed)Co-amoxiclav 1.2g TDS IV or Flucloxacillin 1–2g QDS IV
MRSA risk factorsAdd Vancomycin or use Daptomycin; swab before starting
Necrotising fasciitisEmergency surgery + Meropenem + Clindamycin + Vancomycin
Duration5–7 days for cellulitis
Mark cellulitis border with skin marker on admission — monitor for progression vs. improvement at each nursing assessment.
📈OPAT — Outpatient Parenteral Antibiotic Therapy
OPAT is growing rapidly in GCC private sector. Patients receive IV antibiotics at home or in infusion centres, avoiding hospitalisation.
- Common indications: Osteomyelitis, SSTI, OPAT for endocarditis completion, complicated UTI
- Common drugs: Ceftriaxone OD, Ertapenem OD, Daptomycin OD
- Nurse role: PICC/midline care, drug preparation, patient education, complication monitoring
- Monitor: Renal function, LFTs, FBC weekly; infusion reactions
- Requires robust patient education on line care and when to seek help
🔎 Antibiotic Duration & IV-to-Oral Checker
✅Pre-Administration Antibiotic Check
0 / 8 completed
⌚Timing & Administration Compliance
- Sepsis first dose — administer within 1 hour of prescribing
- Document actual administration time (not prescribed time)
- Missed or delayed doses — document reason in nursing notes
- Infusion rate — check SPC; some antibiotics (e.g., vancomycin) must be infused slowly to avoid reactions
- Prolonged infusion — some beta-lactams (pip-taz, meropenem) benefit from 3–4h extended infusion (pharmacodynamic optimisation)
- Check IV site before and after administration — extravasation risk
⚠️Allergy Documentation — Critical
Penicillin allergy label: 80–90% of patients labelled "penicillin allergic" are NOT truly allergic. Incorrect allergy labelling leads to use of broader, more toxic, more expensive antibiotics.
Document the REACTION, not just "allergic"
Type I (IgE-mediated)Urticaria, angioedema, anaphylaxis — true allergy, use alternative
Non-immune reactionRash (maculopapular, non-urticarial), GI upset — may tolerate cephalosporins
Side effectNausea, diarrhoea — NOT an allergy; document as intolerance
Unknown reactionDocument as unknown; refer for allergy review
Cephalosporin cross-reactivity with penicillin is <2% (side-chain specific). Carbapenems cross-reactivity <1%. Do not automatically substitute vancomycin for amoxicillin without allergy assessment.
📚Patient Education on Antibiotics
0 / 6 completed
"Always complete the full course" is outdated advice for many infections. Emerging evidence supports stopping when clinically well. Advise patients to follow the prescribed course length — not assume they need more.
💩C. difficile Monitoring
- Any patient on antibiotics with >3 loose/watery stools in 24h — suspect C. diff
- Send stool sample for C. difficile toxin BEFORE any anti-motility agents (loperamide)
- Do NOT give loperamide to suspected C. diff — risk of toxic megacolon
- Implement contact precautions immediately pending result
- Alcohol gel does NOT kill C. diff spores — use soap and water for hand hygiene
- Avoid PPIs if clinically safe — they increase C. diff risk
- Antibiotics most associated: Clindamycin, fluoroquinolones, broad-spectrum cephalosporins
- Treatment: Fidaxomicin (preferred) or oral vancomycin (125mg QDS x10d)
🍄Antifungal Stewardship Basics
Azole prophylaxis and empirical antifungal therapy are commonly overused. Antifungal stewardship is an integral part of AMS programmes.
- Candida colonisation ≠ infection — do not treat a positive swab without clinical infection
- Candida in urine — usually colonisation; treatment only if symptomatic or immunocompromised
- Candidaemia — always treat; remove central lines; echo to exclude endocarditis; ophthalmology review
- Fluconazole has excellent oral bioavailability — IV→PO switch when tolerating
- Azole interactions — check for CYP450 interactions (warfarin, tacrolimus, statins)
- Echinocandins (caspofungin, micafungin) — first-line for severe candidaemia
🇦🇪DHA AMS Programme — Dubai
- DHA mandates AMS committees in all licensed hospitals and day surgery centres
- Annual hospital antibiogram required — must inform empirical prescribing guidelines
- AMS pharmacist and/or physician lead required per facility
- Point-prevalence surveys conducted regularly; results reported to DHA
- Antibiotic prescription restriction tiers: unrestricted, restricted, reserve
- Reserve antibiotics (colistin, linezolid, ceftazidime-avibactam) require ID/AMS approval
🇸🇦Saudi MOH — Antibiogram & AMS
- Saudi MOH publishes the National Antibiogram Report annually — available on MOH portal
- CBAHI (Central Board for Accreditation of Healthcare Institutions) AMS standards
- Saudi Centre for Disease Control (Saudi CDC) coordinates national AMR surveillance
- AMS committees mandatory in all MOH hospitals >50 beds
- Antibiotic formulary restricted by facility tier; referral hospitals have broader formulary
- Saudi AMS guidelines (MMID) updated 2023 — align with WHO Access/Watch/Reserve classification
🇶🇦Qatar — National AMS Programme (QNMDR)
- Qatar National AMR and AMS Programme coordinated by Ministry of Public Health (MoPH)
- QNMDR — Qatar National Multidrug Resistance Programme for surveillance
- HMC (Hamad Medical Corporation) has a dedicated antimicrobial stewardship programme
- Antibiotic treatment guidelines published for all major infectious syndromes
- Electronic prescribing systems include hard stops for restricted antibiotics
🕋Hajj Antimicrobial Stewardship
During Hajj season, approximately 2.5 million pilgrims arrive in Saudi Arabia from >180 countries, bringing diverse resistance patterns. Antibiotic use surges dramatically in Makkah and Madinah hospitals.
- Pilgrims arrive with community-acquired infections (RTI, GI, UTI) + travel-associated infections
- ESBL and NDM-producing organisms imported from South Asia, Africa — high colonisation rates
- Hajj hospitals have specific antibiotic protocols reflecting imported organism risks
- AMS during Hajj: rapid diagnostics, strict formulary, culture-guided therapy
- Post-Hajj — pilgrims can carry resistant organisms back to home countries (global spread)
👥The Pharmacist–Nurse–Physician AMS Triad
Physician
- Prescribes antibiotics
- Reviews cultures & de-escalates
- Documents indication & duration
- Approves restricted agents
Pharmacist
- Antibiotic review on ward rounds
- Therapeutic drug monitoring (TDM)
- IV-to-oral switch recommendations
- Drug interaction checks
- AMS education & audit lead
Nurse
- Timely administration
- Culture collection
- Monitor response & flag concerns
- IV-to-oral switch advocacy
- Infection control compliance
- Patient education
📋AMS Audit Tools — WHO PPS Methodology
- Point Prevalence Survey (PPS) — snapshot of antibiotic use on a given day across a facility
- WHO Global PPS methodology — standardised data collection tool, freely available
- Captures: antibiotic name, indication, dose, route, duration, compliance with guideline
- Results used to: benchmark against peers, identify overuse targets, guide interventions
- Nurses contribute to PPS data collection and ensuring accurate administration records
- Day-of-care surveys can be conducted monthly or quarterly
- Global PPS data from GCC centres shows overall antibiotic prevalence 40–60% (higher than EU average of ~30%)
🌟AMS Nurse Specialist — Emerging Role in GCC
The Antimicrobial Stewardship Nurse Specialist is an emerging senior nursing role now being established in GCC tertiary centres, particularly in UAE and Saudi Arabia.
- Leads nursing AMS education and competency programmes
- Conducts antibiotic prescription audits and feeds back to clinical teams
- Champions IV-to-oral switch programmes across the hospital
- Liaises with infection control, microbiology, and pharmacy
- Develops and monitors nursing AMS protocols and bundles
- Represents nursing on the hospital AMS committee
- Recommended training: ECCMID AMS course, UK ARHAI modules, ID Society AMS certification
📊GCC-Specific Resistance Highlights
These rates reflect published GCC hospital surveillance data (2020–2024). Rates vary between facilities. Always refer to your hospital's current antibiogram — available from your pharmacy or infection control department.
The WHO Access/Watch/Reserve (AWaRe) classification is increasingly used in GCC to guide prescribing. Target: >60% of antibiotic use from the Access category (narrow-spectrum, effective agents).